. Author manuscript; available in PMC: 2021 Feb 1.

Published in final edited form as: Am J Clin Oncol. 2020 Feb;43(2):101–106. doi: 10.1097/COC.0000000000000638

Table 2.

Proportion of subjects undergoing each component of guideline-concordant breast cancer therapy, 1993–2012.

Component of guideline-concordant therapy	No	Yes	Total eligible
Definitive surgical therapy^&	7,926 (7.9)	92,601 (92.1)	100,527
Chemotherapy^$	59,215 (76.5)	18,191 (23.5)	77,406
Endocrine therapy^*	2,540 (16.8)	12,600 (83.2)	15,140

Notes:

Defined as mastectomy or lumpectomy with radiation

Restricted to 77,406 patients who should receive chemotherapy according to NCCN guidelines.

For SEER-Medicare, restricted to subjects diagnosed with breast cancer starting in 2007, enrolled in Medicare Part D, and whose tumors were estrogen-receptor positive.